Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VX-950, an investigational compound being developed by Vertex Pharmaceuticals, was well-tolerated and demonstrated potent antiviral activity in a 14-day phase Ib study in patients with hepatitis C.
Subscribe to our email newsletter
According to the company, the rapid decline in plasma hepatitis C virus-RNA levels observed in patients taking VX-950, together with a viral kinetic analysis that projects the potential duration of treatment required to achieve sustained virologic response, support the evaluation of VX-950 in a novel, three-month combination treatment paradigm.
“The clinical data demonstrate a swift and dramatic decline in viral levels with VX-950, and provide insight into VX-950’s potential to transform future HCV treatment,” said Dr Joshua Boger, CEO of Vertex.
Vertex has now filed an investigational new drug application with the FDA to support phase II clinical development of the drug.